These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 21249653)

  • 1. Laxatives or methylnaltrexone for the management of constipation in palliative care patients.
    Candy B; Jones L; Goodman ML; Drake R; Tookman A
    Cochrane Database Syst Rev; 2011 Jan; (1):CD003448. PubMed ID: 21249653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laxatives for the management of constipation in people receiving palliative care.
    Candy B; Jones L; Larkin PJ; Vickerstaff V; Tookman A; Stone P
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD003448. PubMed ID: 25967924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laxatives for the management of constipation in palliative care patients.
    Miles CL; Fellowes D; Goodman ML; Wilkinson S
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003448. PubMed ID: 17054172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD006332. PubMed ID: 36106667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; MacDonald JK; Parker CE; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD009118. PubMed ID: 27531591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylnaltrexone for opioid-induced constipation in advanced illness.
    Thomas J; Karver S; Cooney GA; Chamberlain BH; Watt CK; Slatkin NE; Stambler N; Kremer AB; Israel RJ
    N Engl J Med; 2008 May; 358(22):2332-43. PubMed ID: 18509120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009118. PubMed ID: 22786523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.
    Chamberlain BH; Cross K; Winston JL; Thomas J; Wang W; Su C; Israel RJ
    J Pain Symptom Manage; 2009 Nov; 38(5):683-90. PubMed ID: 19713070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment of constipation in palliative care.
    Clemens KE; Faust M; Jaspers B; Mikus G
    Curr Opin Support Palliat Care; 2013 Jun; 7(2):183-91. PubMed ID: 23478431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.
    Diego L; Atayee R; Helmons P; von Gunten CF
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):473-85. PubMed ID: 19817669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.
    Gatti A; Sabato AF
    Clin Drug Investig; 2012 May; 32(5):293-301. PubMed ID: 22413747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].
    Bader S; Weber M; Becker G
    Schmerz; 2012 Sep; 26(5):568-86. PubMed ID: 23052993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.
    Lipman AG; Karver S; Cooney GA; Stambler N; Israel RJ
    J Pain Palliat Care Pharmacother; 2011; 25(2):136-45. PubMed ID: 21657861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
    Mehta N; O'Connell K; Giambrone GP; Baqai A; Diwan S
    Postgrad Med; 2016; 128(3):282-9. PubMed ID: 26839023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study.
    Mori M; Ji Y; Kumar S; Ashikaga T; Ades S
    Int J Clin Oncol; 2017 Apr; 22(2):397-404. PubMed ID: 27628064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.
    Slatkin N; Thomas J; Lipman AG; Wilson G; Boatwright ML; Wellman C; Zhukovsky DS; Stephenson R; Portenoy R; Stambler N; Israel R
    J Support Oncol; 2009; 7(1):39-46. PubMed ID: 19278178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial.
    Patel PB; Brett SJ; O'Callaghan D; Anjum A; Cross M; Warwick J; Gordon AC
    Intensive Care Med; 2020 Apr; 46(4):747-755. PubMed ID: 32016532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylnaltrexone: a subcutaneous treatment for opioid-induced constipation in palliative care patients.
    Kyle G
    Int J Palliat Nurs; 2009 Nov; 15(11):533-40. PubMed ID: 20081727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.